Centre for Integrated research into Musculoskeletal Ageing (CIMA) Renewal
Lead Research Organisation:
University of Liverpool
Department Name: Institute of Ageing and Chronic Disease
Abstract
Overview
The MRC-Arthritis Research UK Centre for Integrated Research into Musculoskeletal Ageing (CIMA) is a unique team. CIMA brings in a mix of skills from three major U.K. Universities: Liverpool, Newcastle and Sheffield. It helps doctors and lab scientists to work together to grasp:
1) How our muscles, bones and joints change as we age.
2) How this makes some people prone to problems with these tissues such as arthritis and osteoporosis.
3) What each person can do to reduce the risk of developing these problems.
Progress So Far
CIMA was first funded for 5 years in 2012. CIMA has made great progress in figuring out some key processes in muscles, bones and joints as we age. As well as working out what might reduce the risk of developing these problems, we have also done trials of some likely nutritional agents. These might reduce age-related decline in muscles, bones and joints. We have obtained some early evidence that raising vitamin D may help reduce age-related decline, but putting up nitrate intake may not help. A big limit to expanding research in this important area has also been a lack of well-trained researchers and doctors. So the Centre has also developed and run good training courses to meet this need.
Future: Targets, Treatments & Training
This bid is for 5 more years of funding from the Medical Research Council (MRC) and Arthritis Research UK to help build on this work. Our first phase of funding has let the CIMA members spot certain changes to cells- called epigenetic changes. These seem vital in influencing whether muscles, bones and joint tissues decline quickly or slowly as we age. We plan to do a linked research programme across Liverpool, Newcastle and Sheffield. This will seek to work out the importance of these changes and whether we can modify the changes to reduce the risk of getting muscle, bone and joint problems. We will also work together to look more closely at whether nutrition and exercise can prevent or reduce the risk of these problems. We also plan to expand our training programme so more basic scientists and doctors can do excellent research into these problems. Key results will be shared in papers and meetings. More funding bids will be made to do this work.
Patient View
People with arthritis have helped to shape this bid. By joining a series of "Arthritis Matters" Public Engagement events, for example. These have helped the public grasp CIMA's research and shape future priorities. Above all this includes a grasp of new arthritis treatments and how study findings can benefit patients. We also asked a group of 15 patients to advise on the final lay summary. We think talking to patients often about research and listening to their views makes for better research.
Better Engagement
Going forward, patients and the public will continue to be actively involved by providing insight and valued feedback in many ways. Face to face meetings will remain a key part. And more events will be used, including local, national and global schemes. There will be new work with schools, to share CIMA's work, inspire new ideas and nurture talent. The VOICE North digital platform will support this across the Centre and more widely. The CIMA website will also be kept up to date and advances shared on Twitter. We know most older people don't use these yet, but that could change quickly as access gets easier and cheaper. We expect young people to help make solutions for this. We will also increase our work with drug companies, local authorities and the NHS. This will allow us to develop ways to make sure our findings are quickly put into practice to benefit older people. Arthritis is also one of a key number of conditions included in the NIHR James Lind Alliance Priority Setting Partnership on Ageing and Multiple conditions, led by Newcastle University. This will provide more chances for patients who have arthritis to be involved and link to CIMA.
The MRC-Arthritis Research UK Centre for Integrated Research into Musculoskeletal Ageing (CIMA) is a unique team. CIMA brings in a mix of skills from three major U.K. Universities: Liverpool, Newcastle and Sheffield. It helps doctors and lab scientists to work together to grasp:
1) How our muscles, bones and joints change as we age.
2) How this makes some people prone to problems with these tissues such as arthritis and osteoporosis.
3) What each person can do to reduce the risk of developing these problems.
Progress So Far
CIMA was first funded for 5 years in 2012. CIMA has made great progress in figuring out some key processes in muscles, bones and joints as we age. As well as working out what might reduce the risk of developing these problems, we have also done trials of some likely nutritional agents. These might reduce age-related decline in muscles, bones and joints. We have obtained some early evidence that raising vitamin D may help reduce age-related decline, but putting up nitrate intake may not help. A big limit to expanding research in this important area has also been a lack of well-trained researchers and doctors. So the Centre has also developed and run good training courses to meet this need.
Future: Targets, Treatments & Training
This bid is for 5 more years of funding from the Medical Research Council (MRC) and Arthritis Research UK to help build on this work. Our first phase of funding has let the CIMA members spot certain changes to cells- called epigenetic changes. These seem vital in influencing whether muscles, bones and joint tissues decline quickly or slowly as we age. We plan to do a linked research programme across Liverpool, Newcastle and Sheffield. This will seek to work out the importance of these changes and whether we can modify the changes to reduce the risk of getting muscle, bone and joint problems. We will also work together to look more closely at whether nutrition and exercise can prevent or reduce the risk of these problems. We also plan to expand our training programme so more basic scientists and doctors can do excellent research into these problems. Key results will be shared in papers and meetings. More funding bids will be made to do this work.
Patient View
People with arthritis have helped to shape this bid. By joining a series of "Arthritis Matters" Public Engagement events, for example. These have helped the public grasp CIMA's research and shape future priorities. Above all this includes a grasp of new arthritis treatments and how study findings can benefit patients. We also asked a group of 15 patients to advise on the final lay summary. We think talking to patients often about research and listening to their views makes for better research.
Better Engagement
Going forward, patients and the public will continue to be actively involved by providing insight and valued feedback in many ways. Face to face meetings will remain a key part. And more events will be used, including local, national and global schemes. There will be new work with schools, to share CIMA's work, inspire new ideas and nurture talent. The VOICE North digital platform will support this across the Centre and more widely. The CIMA website will also be kept up to date and advances shared on Twitter. We know most older people don't use these yet, but that could change quickly as access gets easier and cheaper. We expect young people to help make solutions for this. We will also increase our work with drug companies, local authorities and the NHS. This will allow us to develop ways to make sure our findings are quickly put into practice to benefit older people. Arthritis is also one of a key number of conditions included in the NIHR James Lind Alliance Priority Setting Partnership on Ageing and Multiple conditions, led by Newcastle University. This will provide more chances for patients who have arthritis to be involved and link to CIMA.
Technical Summary
The MRC-Arthritis Research UK Centre for Integrated research into Musculoskeletal Ageing (CIMA) brings together scientific and clinical expertise in different disciplines from the universities of Liverpool, Newcastle and Sheffield. Formed in 2012, CIMA has developed an integrated approach to study the effects of ageing on the musculoskeletal system, which has been demonstrably successful. CIMA has focussed activities in areas of critical mass where collaborations have provided enhanced value. These include the role of epigenetic changes in cells and tissues affected by musculoskeletal ageing, development of an assessment protocol for monitoring age-related decline in the musculoskeletal system (the CIMA Toolkit), and proof of principle pre-clinical and human studies to identify interventions that reduce the deleterious effects of ageing on the musculoskeletal system. CIMA has developed an innovative graduate training programme and undertaken well-received public engagement activities. The revised CIMA strategy will be increasingly translational, but informed by basic research. Specifically, we will; determine how epigenetic changes in the ageing musculoskeletal system influence the risk of musculoskeletal disorders, the effect of modification of epigenetic changes on musculoskeletal function, and the effect of lifestyle changes on epigenetic marks and molecules; design and implement interventions based on physical activity, nutrition, anti-inflammatory or age-retarding agents on decline of the ageing musculoskeletal system; extend the CIMA training programme to increase MRes, PhD and clinical training, and; develop engagement and impact activities to increase involvement of patients and the older population, and work with industry and other partners to maximise translation of our research discoveries. Finally, it will provide a resilience that will ensure musculoskeletal ageing moves to the centre of medical research activities within and beyond the UK.
Planned Impact
CIMA renewal will contribute to all key impacts, including advancement of scientific knowledge, health and wellbeing, economic competitiveness, policy development and the provision of skilled people to the workforce. Our activities will supplement and complement existing programmes, harnessing the best practice at each of the centres to deliver excellence at all. In every area, the process will be a dialogue or platform of co-discovery, where both sides benefit from improved knowledge and understanding.
Benefits are targeted to the aging population and those who have conditions that are associated with accelerated ageing, for example those with systemic and local joint inflammation.
Potential impacts to the ageing population from advances in scientific knowledge include:
- direct benefits including learning and empowerment from contributing to the design and delivery of studies
- Improved ability to monitor age-related decline of the entire musculoskeletal system and the effects of potential interventions to reduce this through use of the CIMA Toolkit
- benefits from involvement in effective shared decision making using tools like FRAX for assessing fracture risk.
- wider understanding of musculoskeletal ageing from PPI and patient engagement, VOICENorth (Quote: 'We are volunteering the accumulated knowledge we have gathered over our entire life'.)
- better information about healthy ageing and how to achieve it from better trained experts and improved personal engagement from platforms including VOICENorth online and the MOOC.- enhanced understanding of mechanisms and targets, feeding directly into accelerated novel drug identification and development
- refining outcomes and delivering interventions that improve care and both scientific and clinical practice
Impacts for health and wellbeing include:
- improved pain, function and quality of life from participation in clinical trials and accruing to the wider population once interventions are proven effective
- high standard of care related to being involved in a clinical trial
- avoidance of harm from better targeting of therapy and toxicity identification of widely used drugs, such as paracetamol
- improved treatment options and prognostication
Impacts on economic competitiveness include:
- investment in research, delivering economic benefits for the centre and wider economy by a) health gains net of the cost of delivery, b) GDP gains from the activity and further stimulated activity
- these will come from new biomarkers, assessment tools, nutritional supplements and drugs, training and engagement activity
Impacts on policy development will include:
- benefits of more effective care, driven by NICE and other guidelines
- briefing MPs; advising expert panels, select committees, the Foresight programme (such as 'Future of an Ageing Population', 2016); WHO
- collaboration and advisory work for industry, including the CIMA Industrial Strategy Board
Impacts on provision of skilled workforce will include:
- better education and proactive identification of talented scientists from early identification and support for innovation from school sixth form onwards
- enhanced awareness of musculoskeletal ageing in trainee scientists and clinicians arising from exposure to the CIMA MOOC
- support for MRes and PhD students, postdoctoral and tenured scientists, who will contribute to training the next generation, specifically training to increase understanding of PPI and engagement.
- closer industry links leading to both funding of education and scientific posts by industry and flow of highly skilled workforce between academia and industry
Benefits are targeted to the aging population and those who have conditions that are associated with accelerated ageing, for example those with systemic and local joint inflammation.
Potential impacts to the ageing population from advances in scientific knowledge include:
- direct benefits including learning and empowerment from contributing to the design and delivery of studies
- Improved ability to monitor age-related decline of the entire musculoskeletal system and the effects of potential interventions to reduce this through use of the CIMA Toolkit
- benefits from involvement in effective shared decision making using tools like FRAX for assessing fracture risk.
- wider understanding of musculoskeletal ageing from PPI and patient engagement, VOICENorth (Quote: 'We are volunteering the accumulated knowledge we have gathered over our entire life'.)
- better information about healthy ageing and how to achieve it from better trained experts and improved personal engagement from platforms including VOICENorth online and the MOOC.- enhanced understanding of mechanisms and targets, feeding directly into accelerated novel drug identification and development
- refining outcomes and delivering interventions that improve care and both scientific and clinical practice
Impacts for health and wellbeing include:
- improved pain, function and quality of life from participation in clinical trials and accruing to the wider population once interventions are proven effective
- high standard of care related to being involved in a clinical trial
- avoidance of harm from better targeting of therapy and toxicity identification of widely used drugs, such as paracetamol
- improved treatment options and prognostication
Impacts on economic competitiveness include:
- investment in research, delivering economic benefits for the centre and wider economy by a) health gains net of the cost of delivery, b) GDP gains from the activity and further stimulated activity
- these will come from new biomarkers, assessment tools, nutritional supplements and drugs, training and engagement activity
Impacts on policy development will include:
- benefits of more effective care, driven by NICE and other guidelines
- briefing MPs; advising expert panels, select committees, the Foresight programme (such as 'Future of an Ageing Population', 2016); WHO
- collaboration and advisory work for industry, including the CIMA Industrial Strategy Board
Impacts on provision of skilled workforce will include:
- better education and proactive identification of talented scientists from early identification and support for innovation from school sixth form onwards
- enhanced awareness of musculoskeletal ageing in trainee scientists and clinicians arising from exposure to the CIMA MOOC
- support for MRes and PhD students, postdoctoral and tenured scientists, who will contribute to training the next generation, specifically training to increase understanding of PPI and engagement.
- closer industry links leading to both funding of education and scientific posts by industry and flow of highly skilled workforce between academia and industry
Publications
Mercatelli N
(2017)
MiR-23-TrxR1 as a novel molecular axis in skeletal muscle differentiation.
in Scientific reports
Metcalf LM
(2018)
Validation of calcaneus trabecular microstructure measurements by HR-pQCT.
in Bone
Miller B
(2017)
Altered Bone Mechanics, Architecture and Composition in the Skeleton of TIMP-3-Deficient Mice.
in Calcified tissue international
Mitchell TS
(2017)
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
in Clinical and experimental immunology
Morgan RE
(2018)
Interaction with macrophages attenuates equine fibroblast-like synoviocyte ADAMTS5 (aggrecanase-2) gene expression following inflammatory stimulation.
in Journal of orthopaedic research : official publication of the Orthopaedic Research Society
Mueller AJ
(2017)
Cross-species gene modules emerge from a systems biology approach to osteoarthritis.
in NPJ systems biology and applications
Naylor KE
(2018)
Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
Paggiosi MA
(2018)
Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study.
in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
Panoutsopoulou K
(2017)
Radiographic endophenotyping in hip osteoarthritis improves the precision of genetic association analysis.
in Annals of the rheumatic diseases
Parker AM
(2017)
Quantifying Pelvic Periprosthetic Bone Remodeling Using Dual-Energy X-Ray Absorptiometry Region-Free Analysis.
in Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
Pease LI
(2017)
Cross platform analysis of transcriptomic data identifies ageing has distinct and opposite effects on tendon in males and females.
in Scientific reports
Peramuhendige P
(2018)
TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis.
in Scientific reports
Peters AE
(2018)
The effect of ageing and osteoarthritis on the mechanical properties of cartilage and bone in the human knee joint.
in Scientific reports
Pollock N
(2017)
Denervated muscle fibers induce mitochondrial peroxide generation in neighboring innervated fibers: Role in muscle aging.
in Free radical biology & medicine
Proctor CJ
(2017)
Using computer simulation models to investigate the most promising microRNAs to improve muscle regeneration during ageing.
in Scientific reports
Proctor CJ
(2017)
Computer simulation models as a tool to investigate the role of microRNAs in osteoarthritis.
in PloS one
Ramanathan K
(2018)
Neutrophil activation signature in juvenile idiopathic arthritis indicates the presence of low-density granulocytes.
in Rheumatology (Oxford, England)
Ranganath LR
(2018)
Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
in Molecular genetics and metabolism
Rice SJ
(2018)
Identification of a novel, methylation-dependent, RUNX2 regulatory region associated with osteoarthritis risk.
in Human molecular genetics
Rider LG
(2017)
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects.
in Rheumatology (Oxford, England)
Rogers EH
(2017)
Comparing Circadian Dynamics in Primary Derived Stem Cells from Different Sources of Human Adult Tissue.
in Stem cells international
Rotherham M
(2018)
Remote regulation of magnetic particle targeted Wnt signaling for bone tissue engineering.
in Nanomedicine : nanotechnology, biology, and medicine
Rothwell S
(2017)
Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum.
in Arthritis & rheumatology (Hoboken, N.J.)
Rubio-Martínez LM
(2017)
Local anaesthetics or their combination with morphine and/or magnesium sulphate are toxic for equine chondrocytes and synoviocytes in vitro.
in BMC veterinary research
Sabah SA
(2018)
The risk of cardiac failure following metal-on-metal hip arthroplasty.
in The bone & joint journal
Sakellariou GK
(2018)
Comparison of Whole Body SOD1 Knockout with Muscle-Specific SOD1 Knockout Mice Reveals a Role for Nerve Redox Signaling in Regulation of Degenerative Pathways in Skeletal Muscle.
in Antioxidants & redox signaling
Salam S
(2018)
Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy.
in Journal of the American Society of Nephrology : JASN
Schwartz JB
(2018)
Determination of Free 25(OH)D Concentrations and Their Relationships to Total 25(OH)D in Multiple Clinical Populations.
in The Journal of clinical endocrinology and metabolism
Segna D
(2018)
Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts.
in Journal of internal medicine
Shepherd C
(2018)
Functional Characterization of the Osteoarthritis Genetic Risk Residing at ALDH1A2 Identifies rs12915901 as a Key Target Variant.
in Arthritis & rheumatology (Hoboken, N.J.)
Shepstone L
(2018)
Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial.
in Lancet (London, England)
Sleeman I
(2017)
The Role of Vitamin D in Disease Progression in Early Parkinson's Disease.
in Journal of Parkinson's disease
Smith KD
(2017)
Variation in the Quantity of Elastic Fibres with Degeneration in Canine Cranial Cruciate Ligaments from Labrador Retrievers.
in Veterinary and comparative orthopaedics and traumatology : V.C.O.T
Smith NT
(2018)
Redox responses are preserved across muscle fibres with differential susceptibility to aging.
in Journal of proteomics
Sommerville EW
(2017)
Clinical Features, Molecular Heterogeneity, and Prognostic Implications in YARS2-Related Mitochondrial Myopathy.
in JAMA neurology
Sophocleous A
(2017)
Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition.
in Aging cell
Steinberg J
(2018)
Widespread epigenomic, transcriptomic and proteomic differences between hip osteophytic and articular chondrocytes in osteoarthritis.
in Rheumatology (Oxford, England)
Steinberg J
(2017)
Integrative epigenomics, transcriptomics and proteomics of patient chondrocytes reveal genes and pathways involved in osteoarthritis.
in Scientific reports
Stevenson EJ
(2018)
Protein for Life: Towards a focussed dietary framework for healthy ageing.
in Nutrition bulletin
Stokes VJ
(2017)
Hypercalcemic Disorders in Children.
in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Szulc P
(2017)
Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.
in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
Tanaka M
(2017)
Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.
in BMC musculoskeletal disorders
Thalayasingam N
(2018)
CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis: Implications for Causal Gene Identification.
in Arthritis & rheumatology (Hoboken, N.J.)
Thankamony A
(2018)
Compositional marker in vivo reveals intramyocellular lipid turnover during fasting-induced lipolysis.
in Scientific reports
Thorpe CT
(2017)
Fascicles and the interfascicular matrix show decreased fatigue life with ageing in energy storing tendons.
in Acta biomaterialia
Tuck S
(2018)
Implications of guidelines for osteoporosis and its treatment.
in Age and ageing
Turlo AJ
(2018)
Donor age affects proteome composition of tenocyte-derived engineered tendon.
in BMC biotechnology
| Description | ARUK (Bou-Gharios) |
| Amount | £413,430 (GBP) |
| Organisation | Versus Arthritis |
| Start | |
| Description | ARUK (Bou-Gharios) |
| Amount | £251,000 (GBP) |
| Organisation | Versus Arthritis |
| Start | |
| Description | Association of Physicians (Hannan) |
| Amount | £19,850 (GBP) |
| Organisation | Association of Physicians of Great Britain and Ireland |
| Sector | Learned Society |
| Country | United Kingdom |
| Start | |
| Description | BBSRC CRISPR-interference Screening Centre (Eeden, Renshaw, Wilkinson) |
| Amount | £428,223 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | BBSRC In Vivo Skills award (Pekovic-Vaughan et al) |
| Amount | £12,300 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | BBSRC Summer studentship (Peffers) |
| Amount | £2,500 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | BRC MIlkMAN (Granic, Stevenson, Aspray, Sayer) |
| Amount | £91,041 (GBP) |
| Organisation | British Retail Consortium |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | CRUK Pioneer Award (Zglinicki) |
| Amount | £200,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Circadian rhythms and the control of NRF2-based antioxidant signalling as a therapeutic target in dermal tissue repair and pathological wound healing |
| Amount | £448,442 (GBP) |
| Funding ID | MR/P003311/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 01/2020 |
| Description | Dowager Countees Eleanor Peel Trust (Henstock) |
| Amount | £13,500 (GBP) |
| Organisation | The Dowager Countess Eleanor Peel Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Dunhill Medical Trust (Clegg, Screen, Thorpe) |
| Amount | £250,000 (GBP) |
| Organisation | The Dunhill Medical Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Dunhill Medical Trust (Whysall) |
| Amount | £197,222 (GBP) |
| Organisation | The Dunhill Medical Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | EU Marie Curie (Bernut, Renshaw) |
| Amount | £161,000 (GBP) |
| Organisation | Marie Curie |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Health Education England NE (Birrell) |
| Amount | £49,500 (GBP) |
| Organisation | Health Education England |
| Sector | Public |
| Country | Unknown |
| Start | |
| Description | Identification of cytokines that drive progression of fibrosis in Dupuytren's disease: therapeutic opportunities with biologics |
| Amount | £177,383 (GBP) |
| Funding ID | 21809 |
| Organisation | Versus Arthritis |
| Start | 05/2018 |
| End | 07/2020 |
| Description | Illix Ltd (Wright, Moots, Edwards) |
| Amount | £55,994 (GBP) |
| Organisation | Illix Ltd |
| Start | |
| Description | Innovate UK (Hill) |
| Amount | £350,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | JGW Patterson Foundation (Sorial/Loughlin/Deehan) |
| Amount | £52,000 (GBP) |
| Organisation | The JGW Patterson Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | KTP award (Miwa/Zglinicki) |
| Amount | £181,000 (GBP) |
| Organisation | Knowledge Transfer Partnerships |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | MRC (Renshaw et al) |
| Amount | £686,584 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | MRC Project grant (Renshaw) |
| Amount | £691,917 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | MRC iCASE Studentships (Renshaw et al) |
| Amount | £289,023 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Multi-modal high resolution preclinical PET+SPECT+CT scanner |
| Amount | £939,518 (GBP) |
| Funding ID | 208389/Z/17/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 01/2022 |
| Description | NC3R grant (Shanley) |
| Amount | £389,043 (GBP) |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | NIHR HTA (Meher, Hannan) |
| Amount | £2,100,000 (GBP) |
| Organisation | National Institute for Health Research |
| Department | Health Technology Assessment Programme (HTA) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | NIHR Newc BRC Project Grant (Birrell) |
| Amount | £60,824 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Newcastle Hospital Trust (Young, Loughlin) |
| Amount | £44,000 (GBP) |
| Organisation | Newcastle upon Tyne Hospitals NHS Foundation Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | PROvision of braces for Patients with knee OsteoArthritis (PROP OA): a randomised controlled trial |
| Amount | £1,622,564 (GBP) |
| Funding ID | HTA/16/160/03 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 11/2022 |
| Description | Preventing falls in older people by an innovative connected shoe: development & biomechanics study |
| Amount | £575,432 (GBP) |
| Funding ID | 104142 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2020 |
| Description | Royal College Surgeons Edinburgh (Sorial/Loughlin) |
| Amount | £60,000 (GBP) |
| Organisation | The Royal College of Surgeons of Edinburgh |
| Sector | Learned Society |
| Country | United Kingdom |
| Start | |
| Description | Sarcoma UK (Peffers, Balaskas) |
| Amount | £20,750 (GBP) |
| Organisation | Sarcoma UK |
| Sector | Charity/Non Profit |
| Country | Unknown |
| Start | |
| Description | UK Space Agency MICROAGE (Jackson, McArdle, Henstock, Hoettges) |
| Amount | £1,291,511 (GBP) |
| Organisation | UK Space Agency |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Understanding the mechanisms and therapeutic potential of targeting biological clocks in Systemic Sclerosis |
| Amount | £20,598 (GBP) |
| Funding ID | M709 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2017 |
| End | 04/2021 |
| Description | Uni of Georgia pump-priming award (Henstock) |
| Amount | £1,000 (GBP) |
| Organisation | University of Georgia |
| Sector | Academic/University |
| Country | United States |
| Start | |
| Description | University of Liverpool (Pefers) |
| Amount | £6,300 (GBP) |
| Organisation | University of Liverpool |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Wellcome Trust Summer Scholarship (Henstock) |
| Amount | £2,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | What really moves you? Public lectures on the wonders of your musculoskeletal system - public talk |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Oral presentation to approx 60-70 general public attendees ranging in age from primary school to retired adults, followed by questions and answers |
| Year(s) Of Engagement Activity | 2016 |